Clinical trials: Mild to Moderate Acute Respiratory Distress Syndrome
Mild to Moderate Acute Respiratory Distress Syndrome
Post-Market Study of Low-flow ECCO2R Using PrismaLung+
PrismaLung+ is intended to provide extracorporeal carbon dioxide removal (ECCO2R) as a standalone therapy or in combination with continuous renal replacement therapy (CRRT).
- Trial name
- NCT04617093
- Testing
- PrismaLung+
- Where
- 10 sites in France
- Volunteers
- 63 people
- Sponsor
- Vantive Health LLC
Acute Respiratory Failure
Physiological Effects of a New Interface on Lung Ventilation and Gas Distribution
Hypoxemic Acute Respiratory Failure (hARF) is a common reason of admission to Intensive Care. Different modalities can be used to administer oxygen, which is the first supportive treatment in these patients.
- Trial name
- NCT04619641
- Testing
- High Flow Nasal Cannula (HFNC), Continuous Positive Airway Pressure (CPAP)
- Volunteers
- 15 people
- Sponsor
- University Magna Graecia
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
ARDS (Acute Respiratory Distress Syndrome)
Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunteers and in patients with mild-to-moderate acute respiratory distress…
- Trial name
- NCT07449572
- Testing
- HT31-1, Saline (0.9%, sterile, for infusion)
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HTIC, Inc
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19.
- Trial name
- NCT05212662
- Testing
- TTI-0102
- Sponsor
- Thiogenesis Therapeutics, Inc.
Acute Respiratory Distress Syndrome
Low-Flow CO2 Removal for Mild to Moderate ARDS With PRISMALUNG
This pilot observational study will assess changes in pH /PaO2 /PaCO2, Respiratory Rate and device CO2 clearance in the first 24 hours of Extracorporeal CO2 removal (ECCO2R) following tidal volume (Vt), and plateau pressure…
- Trial name
- NCT02606240
- Testing
- CO2 removal with PRISMALUNG in ARDS
- Where
- 5 sites in France
- Volunteers
- 20 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Neonatal Respiratory Distress Syndrome
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
The present study will mainly aim at investigating the safety, tolerability and efficacy of different escalating single doses administration of nebulised Curosurf®, in preterm neonates with RDS (Respiratory Distress Syndrome)…
- Trial name
- NCT03235986
- Testing
- nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I), nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II), nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
- Where
- Italy
- Volunteers
- 166 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Respiratory Distress Syndrome
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Mild to Moderate Acute Respiratory Distress Syndrome (ARDS)…
- Trial name
- NCT05983627
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
ARDS, Acute Respiratory Distress Syndrome
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
Acute respiratory distress syndrome (ARDS) accounts for almost 10% of intensive care units (ICU) admissions. Three ARDS stages have been defined, based on the PaO2/FIO2 ratio measured with positive end-expiratory pressure (PEEP)…
- Conditions
- ARDS, Acute Respiratory Distress Syndrome, Intensive Care Unit, Mechanical Ventilation
- Trial name
- PROMILD (NCT05056090)
- Testing
- Patients will receive MV in PP
- Where
- France
- Volunteers
- 656 people
- Sponsor
- University Hospital, Grenoble
PaO2/FiO2 Ratio
The Effect of FiO2 on PaO2/FiO2 Ratio
The PaO2/FiO2 ratio is frequently used to determine the severity of lung injury in mechanically ventilated patients. However, several mathematical models have shown that PaO2/FiO2 ratio depends on FiO2.
- Trial name
- NCT03156218
- Testing
- Modulation of FiO2
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
ARDS
Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS
This is phase IIb, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 of one dose 10^10 exosome particles, to Prevent Clinical Deterioration in Patients with…
- Trial name
- NCT05947747
- Testing
- EXO-CD24
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Nano24med
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Acute Respiratory Failure
Effects of a New Interface for NIV on Respiratory Drive
This pilot physiologic randomized cross-over study was designed to investigate if, in patients with hARF, a new device combining high-flow oxygen through nasal cannula (HFNC) and continuous positive airway pressure (CPAP) reduces…
- Trial name
- NCT04619667
- Testing
- High Flow Nasal Cannula (HFNC), Continuous Positive Airway Pressure (CPAP)
- Volunteers
- 22 people
- Sponsor
- University Magna Graecia
Newborn Respiratory Distress Syndrome
HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP for Respiratory Distress Syndrome of Prematurity
Preterm infants ranging from 29+0 to 36+6 weeks+days are randomly assigned to one of the following treatments as non invasive respiratory support if they develop mild to moderate Respiratory Distress Syndrome within 72 hrs from…
- Trial name
- NCT02570217
- Testing
- HHHFNC, NCPAP
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Coronavirus Infections, Pneumonia, Viral
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019.
- Conditions
- Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- NoCovid (NCT04305457)
- Testing
- Nitric Oxide
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital